Author(s):
Sanchari Bhattacharya, Ishita Debnath, Rajarshi Kasyapi, Padmanava Seth, Arnob Halder, Sudipta Halder
Email(s):
sanchari.bhattacharya@gnipst.ac.in
DOI:
10.52711/0974-360X.2026.00624 
Address:
Sanchari Bhattacharya*, Ishita Debnath, Rajarshi Kasyapi, Padmanava Seth, Arnob Halder, Sudipta Halder
Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157F, Nilgunj Road, Panihati, Sodpur, Kolkata 700114, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 9,
Year - 2026
ABSTRACT:
Conventional cancer treatments frequently fail because of metastasis, resistance, and serious side effects, making it one of the major causes of death globally. Because of their special qualities, including their capacity to target tumors, modulate the immune system, and promote regeneration, stem cell-based treatments have attractive substitutes. A thorough comparison of the various types of stem cells, their processes, and their therapeutic usefulness is still lacking despite the large amount of research on the application of stem cells in oncology. Furthermore, more research is needed to address issues like tumorigenicity, ethical dilemmas, and delivery efficacy. Emphasizing on their mechanisms of action, therapeutic uses, and transitional hurdles, this review critically investigates the function of stem cells in cancer therapy. Here we compared the therapeutic potential and limits of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), along with induced pluripotent stem cells(iPSCs). The tumor-homing capacity of MSCs makes them extremely promising, but iPSCs provide a patient-specific, renewable cell supply that can be used in CAR-T therapy. However, their broad clinical acceptance is hampered by issues with immunological rejection, malignancy, and regulatory limitations. A paradigm shift in oncology, stem cell-based cancer therapies provide novel approaches to cancer that are resistant to treatment. Future success depends on resolving safety issues, improving gene-editing methods, and maximizing clinical translation. This review highlights important topics for further study and offers suggestions for overcoming the present constraints.
Cite this article:
Sanchari Bhattacharya, Ishita Debnath, Rajarshi Kasyapi, Padmanava Seth, Arnob Halder, Sudipta Halder. Exploring the Role of Stem Cells in Cancer Therapy, Highlighting the risk-benefit Analysis. Research Journal Pharmacy and Technology. 2026;19(9):4481-8. doi: 10.52711/0974-360X.2026.00624
Cite(Electronic):
Sanchari Bhattacharya, Ishita Debnath, Rajarshi Kasyapi, Padmanava Seth, Arnob Halder, Sudipta Halder. Exploring the Role of Stem Cells in Cancer Therapy, Highlighting the risk-benefit Analysis. Research Journal Pharmacy and Technology. 2026;19(9):4481-8. doi: 10.52711/0974-360X.2026.00624 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-9-70
10. REFERENCES:
1. Kumar A, Singh K, Kumar K, Singh A, Tripathi A, Tiwari L. Drug resistance in cancer therapy: mechanisms, challenges and strategies. Asian J Nurs Educ Res. 2024;14(1):95-100.
2. Masule A, M. Murari V. Utilization of Stem Cells for Cancer Treatment- A Review. AJPR; 2023. Nov (22): 269–76.
3. Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, Zhai Z, Tanzhu G, Yang J, Zhou R. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024; 9(1): 170. https://doi.org/10.1038/s41392-024-01851-y
4. Chu DT, Nguyen TT, Tien NLB, Tran DK, Jeong JH, Anh PG, et al. Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications. Cells; 2020 Feb 28. 9(3): 563.
5. Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges. Cell Stem Cell; 2020 Oct. 27(4): 523–31.
6. Kim HY, Yoon HS, Lee Y, Kim YH, Cho KA, Woo SY, Kim HS, Ryu KH, Park JW. Matrix Metalloproteinase 1 as a marker of tonsil-derived mesenchymal stem cells to assess bone marrow cell migration. Tissue Eng Regen Med. 2023; 20(2): 271-284. https://doi.org/10.1007/s13770-022-00501-0
7. Tian Z, Yu T, Liu J, Wang T, Higuchi A. Introduction to stem cells. In: Progress in Molecular Biology and Translational Science [Internet]. Elsevier; 2023 [cited 2024 Dec 19]. p. 3–32.
8. Taherian M, Bayati P, Mojtabavi N. Stem cell-based therapy for fibrotic diseases: mechanisms and pathways. Stem Cell Res Ther. 2024; 15(1): 170. https://doi.org/10.1186/s13287-024-03782-5
9. Konde P, Game R, Urhe M, Shinde A. Immunity management post cancer therapy. Asian J Pharm Res. 2022; 12(1): 24-8.
10. Aldoghachi AF, Chong ZX, Yeap SK, Cheong SK, Ho WY, Ong AHK. Stem Cells for Cancer Therapy: Translating the Uncertainties and Possibilities of Stem Cell Properties into Opportunities for Effective Cancer Therapy. IJMS; 2023 Jan 5. 24(2): 1012.
11. Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Sig Transduct Target Ther; 2020 Feb 7. 5(1): 8.
12. Rezayatmand H, Razmkhah M, Razeghian-Jahromi I. Drug resistance in cancer therapy: the Pandora’s Box of cancer stem cells. Stem Cell Res Ther; 2022 Dec. 13(1): 181.
13. Deka K, Li Y. Transcriptional regulation during aberrant activation of NF-κB signalling in cancer. Cells. 2023; 12(5): 788. https://doi.org/10.3390/cells12050788
14. Chu DT, Nguyen TT, Tien NLB, Tran DK, Jeong JH, Anh PG, et al. Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications. Cells; 2020 Feb 28. 9(3): 563.
15. Maya Y. Gaikwad, Neha Kharat. Immunotherapy in Cancer its Recent Advances and Challenges. Asian Journal of Pharmacy and Technology. 2025; 15(1): 57-5.
16. Sun W, Huang X. Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy. Chin Med J (Engl). 2022; 135(8): 890-900. https://doi.org/10.1097/CM9.0000000000001898
17. Kharouf N, Flanagan TW, Hassan SY, Shalaby H, Khabaz M, Hassan SL, Megahed M, Haikel Y, Santourlidis S, Hassan M. Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment. Cancers. 2023; 15(12): 3147. https://doi.org/10.3390/cancers15123147
18. Aldoghachi AF, Chong ZX, Yeap SK, Cheong SK, Ho WY, Ong AHK. Stem Cells for Cancer Therapy: Translating the Uncertainties and Possibilities of Stem Cell Properties into Opportunities for Effective Cancer Therapy. IJMS; 2023 Jan 5. 24(2): 1012.
19. Yamada Y, Nguyen TT, Impellizzieri D, Mineura K, Shibuya R, Gomariz A, Haberecker M, Nilsson J, Nombela-Arrieta C, Jungraithmayr W, Boyman O. Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice. Nat Commun. 2023; 14(1): 1383. https://doi.org/10.1038/s41467-023-36924-z
20. Mehrani Y, Morovati S, Keivan F, Sarmadi S, Shojaei S, Forouzanpour D, Bridle BW, Karimi K. Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Efficacy. Cells. 2025; 14(11): 812. https://doi.org/10.3390/cells14110812
21. Slama Y, Ah-Pine F, Khettab M, Arcambal A, Begue M, Dutheil F, Gasque P. The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential. Int J Mol Sci. 2023; 24(17): 13511. https://doi.org/10.3390/ijms241713511
22. Hazrati A, Malekpour K, Mirsanei Z, Khosrojerdi A, Rahmani-Kukia N, Heidari N, Abbasi A, Soudi S. Cancer-associated mesenchymal stem/stromal cells: role in progression and potential targets for therapeutic approaches. Front Immunol. 2023; 14: 1280601. https://doi.org/10.3389/fimmu.2023.1280601
23. Ray A. Scope of embryonic stem cells in research. Asian J Nurs Educ Res. 2012; 2(2): 51-4.
24. Mahasa KJ, De Pillis L, Ouifki R, Eladdadi A, Maini P, Yoon AR, et al. Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci Rep; 2020 Jan 16. 10(1): 425.
25. Starska-Kowarska K. Role of Mesenchymal Stem/Stromal Cells in Head and Neck Cancer-Regulatory Mechanisms of Tumorigenic and Immune Activity, Chemotherapy Resistance, and Therapeutic Benefits of Stromal Cell-Based Pharmacological Strategies. Cells. 2024; 13(15): 1270. https://doi.org/10.3390/cells13151270
26. Chang DY, Jung JH, Kim AA, Marasini S, Lee YJ, Paek SH, Kim SS, Suh-Kim H. Combined effects of mesenchymal stem cells carrying cytosine deaminase gene with 5-fluorocytosine and temozolomide in orthotopic glioma model. Am J Cancer Res; 2020 May 1. 10(5): 1429-1441.
27. Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Sig Transduct Target Ther; 2021 Mar 26. 6(1): 127.
28. Dai X, Feng S, Zheng Y. Cold Atmospheric Plasma: Possible Cure of Autoimmune Disorders and Cancer via Attenuating Inflammation. Int J Biol Sci. 2024; 20(14): 5436-5449. https://doi.org/10.7150/ijbs.102445
29. Landeros N, Castillo I, Pérez-Castro R. Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer. Cells. 2023; 12(5): 720. https://doi.org/10.3390/cells12050720
30. Patil K, Khan FB, Akhtar S, Ahmad A, Uddin S. The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance. Cancer Metastasis Rev. 2021; 40(3): 691-720. https://doi.org/10.1007/s10555-021-09979
31. Dhakad GG, Shirsat SP, Tambe KP, Kairnar V, Jain RS. Review on immuno-oncology agents for cancer therapy. Asian J Pharm Res. 2022;12(1):110-5.
32. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J; 2021 Apr 6. 11(4): 69.
33. Thambi T, Hong J, Yoon AR, Yun CO, et al. Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses. Cancer Gene Ther. 2022; 29(10): 1321-1331. https://doi.org/10.1038/s41417-022-00469-y
34. Abas BI, Demirbolat GM, Cevik O, et al. Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel. PLoS One. 2022; 17(9): e0274607. https://doi.org/10.1371/journal.pon
35. Kamarehei F. The effects of combination therapy by solid lipid nanoparticle and dental stem cells on different degenerative diseases. Am J Transl Res. 2022;14(5):3327-3343.
36. Zhou H, Tan L, Liu B, Guan XY. Cancer stem cells: recent insights and therapies. Biochem Pharmacol. 2023; 209: 115441. https://doi.org/10.1016/j.bcp.2023.115441
37. Cobaleda C, Sánchez-García I. Leukemia Stem Cell Drug Discovery. Methods Mol Biol; 2021. 2185: 39-48.
38. Long NA, Golla U, Sharma A, Claxton DF. Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications. Stem Cell Rev and Rep; 2022 Apr. 18(4): 1211–26.
39. Henry E, Arcangeli ML. How hematopoietic stem cells respond to irradiation: similarities and differences between low and high doses of ionizing radiations. Exp Hematol. 2021; 94: 11-19. https://doi.org/10.1016/j.exphem.2020.12.001
40. Azar J, Bahmad HF, Daher D, Moubarak MM, Hadadeh O, Monzer A, Al Bitar S, Jamal M, Al-Sayegh M, Abou-Kheir W. The use of stem cell-derived organoids in disease modeling: an update. Int J Mol Sci. 2021; 22(14): 7667. https://doi.org/10.3390/ijms22147667
41. Porter RJ, Murray GI, McLean MH. Current concepts in tumour-derived organoids. Br J Cancer; 2020 Oct. 123(8): 1209-1218.
42. Saraswat D, Singh HM. Effectiveness of structured teaching programme on knowledge regarding umbilical cord stem cell therapy among staff nurses in Apollo Hospital at Gandhinagar, Gujarat. Int J Nurs Educ Res. 2021; 9(2): 164-6.
43. Taurin S, Alzahrani R, Aloraibi S, Ashi L, Alharmi R, Hassani N. Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy. Translational Oncology; 2025 Jan. 51: 102226.
44. Jangde R. An overview of resealed erythrocyte for cancer therapy. Asian J Res Pharm Sci. 2011; 1(4): 83-92.
45. Holokai L, Chakrabarti J, Lundy J, Croagh D, Adhikary P, Richards SS, Woodson C, Steele N, Kuester R, Scott A, Khreiss M. Murine-and human-derived autologous organoid/immune cell co-cultures as pre-clinical models of pancreatic ductal adenocarcinoma. Cancers. 2020 Dec 17; 12(12): 3816.
46. Montazersaheb S, Fathi E, Mamandi A, Farahzadi R, Heidari HR. Mesenchymal stem cells and cancer stem cells: an overview of tumor-mesenchymal stem cell interaction for therapeutic interventions. Curr Drug Targets. 2022; 23(1): 60-71.
47. Maradiya J, Doss KJJ. A study to assess the effectiveness of structured teaching programme on knowledge regarding umbilical cord blood stem cell therapy among III year BSc nursing students in a selected nursing college at Rajkot. A&V Publ J Nurs Med Res. 2023; 2(3): 88-90.
48. Movahed AY, Bagheri R, Savatier P, Šarić T, Moradi S. Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: an important step toward ensuring safe cell therapy. Stem Cell Reports. 2025; 20(7): 102543.
49. Takeda M, Ito E, Minami K, Harada A, Mochizuki-Oda N, Sawa Y, Miyagawa S. Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes. Biochemical and biophysical research communications. 2021 Oct 15; 574: 91-6.
50. Peng X, Dong H, Zhang L, Liu S. Role of cancer stem cell ecosystem on breast cancer metastasis and related mouse models. Zoological Res. 2024;45(3):506-517.
51. Vegad K, Kakadia N, Kanaki N. Cell proliferative potential of ethnomedicinal plants for the management of osteoporosis. Res J Pharm Technol. 2021;14(1): 85-90.
52. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. International journal of molecular sciences. 2020 May 2; 21(9): 3233.
53. Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduction and targeted therapy. 2023 Apr 12; 8(1): 160.
54. Arabi TZ, Almasry Y, Xue A, Eirin A, Lerman A, Zhu XY, Lerman LO. Immune rejection of human mesenchymal stem cells compared to extracellular vesicles in mice with renal artery stenosis. Stem Cells Translational Medicine. 2025 Apr; 14(4): szaf015.
55. Rowland AL, Miller D, Berglund A, Schnabel LV, Levine GJ, Antczak DF, Watts AE. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting. Stem cells translational medicine. 2021 May 1; 10(5): 694-710.
56. Lopez-Yus M, García-Sobreviela MP, Del Moral-Bergos R, Arbones-Mainar JM. Gene therapy based on mesenchymal stem cells derived from adipose tissue for the treatment of obesity and its metabolic complications. Int J Mol Sci. 2023; 24(8): 7468.
57. Kwon JH, Kim M, Um S, Lee HJ, Bae YK, Choi SJ, Hwang HH, Oh W, Jin HJ. Senescence-Associated Secretory Phenotype Suppression Mediated by Small-Sized Mesenchymal Stem Cells Delays Cellular Senescence through TLR2 and TLR5 Signaling. Cells. 2021; 10(1): 63.
58. Jwo SH, Ng SK, Li CT, Chen SP, Chen LY, Liu PJ, Wang HJ, Lin JS, Ko CJ, Lee CF, Wang CH, Ouyang X, Wang L, Wei TT. Dual prophylactic and therapeutic potential of iPSC-based vaccines and neoantigen discovery in colorectal cancer. Theranostics. 2025; 15(12): 5890-5908.
59. Parambi DGT, Alharbi KS, Kumar R, Harilal S, Batiha GE, Cruz-Martins N, Magdy O, Musa A, Panda DS, Mathew B. Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases. Mol Neurobiol. 2022; 59(1): 191-233.
60. Shaikhutdinov IH, Ilyasov PV, Gribkova OV, Limareva LV. Non-viral systems for intracellular delivery of genome editing tools. Vavilovskii Zh Genet Selektsii. 2024; 28(2): 239-248.
61. Kuntjoro M, Agustono B, Prasetyo EP, Salim S, Rantam FA, Hendrijantini N. The effect of advanced glycation end products (AGEs) on human umbilical cord mesenchymal stem cells (hUCMSCs) with regard to osteogenesis and calcification. Res J Pharm Technol. 2021; 14(8): 4019-24.
62. Bhatia S, Dai C, Landier W, Hageman L, Wu J, Schlichting E, Siler A, Funk E, Hicks J, Bosworth A, Te HS. Trends in late mortality and life expectancy after allogeneic blood or marrow transplantation over 4 decades: a blood or marrow transplant survivor study report. JAMA oncology. 2021 Nov 1; 7(11): 1626-34.
63. Kelkar AH, Antin JH, Shapiro RM. Long-term health outcomes of allogeneic hematopoietic stem cell transplantation. Frontiers in Oncology. 2023 Apr 12; 13: 1175794.
64. Zirngibl F, Gebert P, Materne B, Launspach M, Künkele A, Hundsdoerfer P, Cyrull S, Deubzer HE, Kühl JS, Eggert A, Lang P. Everolimus with or without Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Children with Acute Kidney Injury: A Single-Center Retrospective Analysis. Transplantation and Cellular Therapy. 2025 Apr 1; 31(4): 257-e1.
65. Yao D, Tian Y, Li J, Li B, Lu J, Ling J, Zheng D, Yao Y, Xiao P, Meng L, Hu S. Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-versus-host disease in pediatric patients with acquired severe aplastic anemia. Therapeutic Advances in Hematology. 2022 Oct; 13: 20406207221134409.
66. Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, Wu J. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Research & Therapy. 2022 Mar 4; 13(1): 93.
67. Murata M, Teshima T. Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem cell products. Frontiers in Immunology. 2021 Aug 19; 12: 724380.
68. Chairul Yahya, Mohammad S. Rohman, Mohammad Hidayat, Alexander P. Nugraha, Fedik A. Rantam. Resveratrol maintain Human Iliac Bone Marrow Mesenchymal Stem Cells Stemness through Sirtuin 1 Mediated Regulation of SRY-Box Transcription Factor 2: an in vitro and in silico study. Research Journal of Pharmacy and Technology. 2022; 15(5): 2313-9.
69. Lombardo G, Lechanteur C, Briquet A, Seidel L, Willems E, Servais S, Baudoux E, Kerre T, Zachee P, Herman J, Janssen A. Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review. Stem Cell Research & Therapy. 2024 Dec 3; 15(1): 461.
70. Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, Wu J. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Research and Therapy. 2022 Mar 4; 13(1): 93.